GSK plc logo

GSK plc

GSK

NYSEHealthcareDrug Manufacturers - General

Previous close

$52.41

+$0.45 · +0.87%

Aug 21, 4:00 PM ET

GSK company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

98

Deep Value

Momentum

48

Neutral

Sentiment

54

Mixed

Risk resilience

77

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.

Industry
Drug Manufacturers - General
Sector
Healthcare
Headquarters
GB
CEO
Luke Victor Miels
Listed since
Mar 28, 1980
Employees
66,841

Market position

Day range

Current $52.41

52-week range

Current $52.41

Open
$51.35
Previous close
$51.96
Volume
2.23M
0.56× average
Average volume
3.96M
Average daily volume
Market cap
105B USD
Beta
0.3
Market reference 1
50-day average
$51.8666
+1.05% above average
200-day average
$52.1116
+0.57% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
88.02B GBP
P/E (TTM)
15.99×
P/B (TTM)
4.36×
P/S (TTM)
2.32×
EV / EBITDA
8.46×
Earnings yield
7.75%
Free cash flow yield
7.90%
Dividend yield
3.54%

Profitability & efficiency

Gross margin
73.29%
Operating margin
24.12%
Net margin
14.52%
Return on equity
34.96%
Return on assets
9.37%
Return on invested capital
16.61%

Financial health

Debt / equity
1.03×
Current ratio
0.82×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends79%53%27%2%Gross margin, FY2021: 66.95%Gross margin, FY2022: 67.42%Gross margin, FY2023: 71.76%Gross margin, FY2024: 71.16%Gross margin, FY2025: 72.40%Operating margin, FY2021: 17.64%Operating margin, FY2022: 21.94%Operating margin, FY2023: 22.24%Operating margin, FY2024: 12.82%Operating margin, FY2025: 25.52%Net margin, FY2021: 17.76%Net margin, FY2022: 51.00%Net margin, FY2023: 16.25%Net margin, FY2024: 8.21%Net margin, FY2025: 17.50%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 66.95%. Gross margin FY2022 67.42%. Gross margin FY2023 71.76%. Gross margin FY2024 71.16%. Gross margin FY2025 72.40%. Operating margin FY2021 17.64%. Operating margin FY2022 21.94%. Operating margin FY2023 22.24%. Operating margin FY2024 12.82%. Operating margin FY2025 25.52%. Net margin FY2021 17.76%. Net margin FY2022 51.00%. Net margin FY2023 16.25%. Net margin FY2024 8.21%. Net margin FY2025 17.50%.

Income trends

Revenue

32.67B GBP+4.11%

Operating income

8.34B GBP+107.36%

Net income

5.72B GBP+121.98%
Income trends across reported periods35.68B GBP23.64B GBP11.6B GBP−434.2M GBPRevenue, FY2021: 24.7B GBPRevenue, FY2022: 29.32B GBPRevenue, FY2023: 30.33B GBPRevenue, FY2024: 31.38B GBPRevenue, FY2025: 32.67B GBPOperating income, FY2021: 4.36B GBPOperating income, FY2022: 6.43B GBPOperating income, FY2023: 6.75B GBPOperating income, FY2024: 4.02B GBPOperating income, FY2025: 8.34B GBPNet income, FY2021: 4.39B GBPNet income, FY2022: 14.96B GBPNet income, FY2023: 4.93B GBPNet income, FY2024: 2.58B GBPNet income, FY2025: 5.72B GBPFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 24.7B GBP. Revenue FY2022 29.32B GBP. Revenue FY2023 30.33B GBP. Revenue FY2024 31.38B GBP. Revenue FY2025 32.67B GBP. Operating income FY2021 4.36B GBP. Operating income FY2022 6.43B GBP. Operating income FY2023 6.75B GBP. Operating income FY2024 4.02B GBP. Operating income FY2025 8.34B GBP. Net income FY2021 4.39B GBP. Net income FY2022 14.96B GBP. Net income FY2023 4.93B GBP. Net income FY2024 2.58B GBP. Net income FY2025 5.72B GBP.
Metric (GBP)FY2025FY2024FY2023FY2022FY2021
Revenue32.67B GBP31.38B GBP30.33B GBP29.32B GBP24.7B GBP
Cost of goods sold9.02B GBP9.05B GBP8.57B GBP9.55B GBP8.16B GBP
Gross profit23.65B GBP22.33B GBP21.76B GBP19.77B GBP16.53B GBP
Research and development7.53B GBP6.4B GBP6.22B GBP5.49B GBP5.02B GBP
Selling, general, and administrative9.09B GBP11.02B GBP9.39B GBP8.37B GBP7.07B GBP
Operating expenses15.31B GBP18.31B GBP15.02B GBP13.34B GBP12.18B GBP
Interest income56M GBP67.39M GBP40M GBP64.27M GBP28M GBP
Interest expense687M GBP657.58M GBP775M GBP855.53M GBP784M GBP
Depreciation and amortization2.31B GBP2.55B GBP2.29B GBP2.15B GBP2.12B GBP
Operating income8.34B GBP4.02B GBP6.75B GBP6.43B GBP4.36B GBP
Net income5.72B GBP2.58B GBP4.93B GBP14.96B GBP4.39B GBP

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
11 beats, 0 misses, 0 met estimates
Average EPS surprise
+12.74%
11 comparable reports
Latest EPS result
1.36
Estimate 1.27 · Beat by 7.09%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.561.170.770.37Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 0.59, estimate 0.44, surprise +34.09%, Beat. Q2 2025, reported Apr 30, 2025: actual 1.13, estimate 1.08, surprise +4.63%, Beat. Q3 2025, reported Jul 30, 2025: actual 1.23, estimate 1.12, surprise +9.82%, Beat. Q4 2025, reported Oct 29, 2025: actual 1.48, estimate 1.26, surprise +17.46%, Beat. Q1 2026, reported Feb 4, 2026: actual 0.68, estimate 0.64, surprise +6.25%, Beat. Q2 2026, reported Apr 29, 2026: actual 1.24, estimate 1.16, surprise +6.90%, Beat. Q3 2026, reported Jul 28, 2026: actual 1.36, estimate 1.27, surprise +7.09%, Beat. Q4 2026, reported Oct 28, 2026: actual —, estimate 1.37, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates12.35B11.25B10.16B9.06BQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 10.16B USD, estimate 9.54B USD, surprise +6.53%, Beat. Q2 2025, reported Apr 30, 2025: actual 10.04B USD, estimate 9.72B USD, surprise +3.33%, Beat. Q3 2025, reported Jul 30, 2025: actual 10.61B USD, estimate 10.5B USD, surprise +1.12%, Beat. Q4 2025, reported Oct 29, 2025: actual 11.32B USD, estimate 11.04B USD, surprise +2.56%, Beat. Q1 2026, reported Feb 4, 2026: actual 11.78B USD, estimate 11.41B USD, surprise +3.23%, Beat. Q2 2026, reported Apr 29, 2026: actual 10.3B USD, estimate 10.23B USD, surprise +0.69%, Beat. Q3 2026, reported Jul 28, 2026: actual 11.18B USD, estimate 11.02B USD, surprise +1.42%, Beat. Q4 2026, reported Oct 28, 2026: actual —, estimate 11.88B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

29 ratings
Strong buy00%
Buy931%
Hold1655%
Sell414%
Strong sell00%

GSK news

Corporate actions

Corporate action history

Stock split

Effective Jul 22, 2022

4:5

Stock split

Effective Nov 12, 1991

2:1

Stock split

Effective Jan 27, 1986

2:1

Stock split

Effective Feb 22, 1983

2:1

Stock split

Effective Feb 13, 1980

2:1

GSK peers

ETFs holding GSK

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research GSK

research.disclaimer